CARDIOVASCULAR COMPLICATIONS AND ENDOTHELIAL DYSFUNCTION IN PRIMARY VASCULITIS
- 作者: Strizhakov L1, Moiseev S1, Semenkova E1, Kuznetsova E1
-
隶属关系:
- I.M. Sechenov First State Medical University
- 期: 卷 84, 编号 5 (2012)
- 页面: 31-35
- 栏目: Editorial
- URL: https://journals.rcsi.science/0040-3660/article/view/31028
- ID: 31028
如何引用文章
全文:
详细
作者简介
L Strizhakov
I.M. Sechenov First State Medical University
Email: strizhakov76@mail.ru
канд. мед. наук, доц. каф. терапии и профболезней
S Moiseev
I.M. Sechenov First State Medical University
Email: clinpharm@mtu-net.ru
д-р мед. наук, проф. каф. терапии и профболезней
E Semenkova
I.M. Sechenov First State Medical Universityд-р мед. наук, проф. каф. терапии и профболезней
E Kuznetsova
I.M. Sechenov First State Medical University
Email: kei1986@mail.ru
клин. ординатор каф. терапии и профболезней
参考
- Hall F. C., Dalbeth N. Disease modification and cardiovascular risk reduction: two sides of the same coin? Rheumatology 2005; 44 (12): 2—10.
- Leuven S. I., Franssen R., Kasteilen J. J. Systemic inflammation as a risk factor for atherosclerosis. Rheumatology 2008; 47: 3—7.
- Насонов Е. Л., Насонова В. А. (ред.). Ревматология: Нац. руководство. М.: Гэотар-Медиа; 2008. 647—660.
- Дряженкова И. В. Поражение сердечно-сосудистой системы при ревматических болезнях. Кардиология 2005; 11: 98—104.
- Шилкина Н. П., Дряженкова И. В. Системные васкулиты и атеросклероз. Тер. арх. 2007; 3: 84—92.
- Насонов Е. Л., Баранов А. А., Шилкина Н. П. Васкулиты и васку-лопатии. Ярославль: Верхняя Волга; 1999.
- Goodson N. J., Wiles N. J., Lunt M. Mortality in early inflammatory polyarthritis. Cardiovascular mortality is increased in seropositive patients. Arthr. and Rheum. 2002; 46: 2010—2019.
- Hetjmancik M. R., Wright J. C., Quint R. et al. The cardiovascular manifestations of systemic lupus erythematosus. Am. Heart J. 1964; 68: 119—130.
- Jensen G., Sigurd B. Systemic lupus erythematosus and acute myocardial infarction. Chest 1973; 64: 653—654.
- Urowitz M. B., Bookman A. A. M., Koehler B. E. et al. The bimodal mortality pattern of systemic lupus erythematosus. Am. J. Med. 1976; 60: 221—225.
- Gladman D. D., Urowitz M. B. Morbidity in systemic lupus erythematosus. J. Rheumatol. 1987; 14 (Suppl. 13): 223—226.
- Ward M. M. Premature morbidity from cardiovascular and cerebrovascular diseases in women with systemic lupus erythematosus. Arthr. and Rheum. 1999; 42: 338—346.
- Bukley B. H., Roberts W. C. The heart in systemic lupus erythematosus and the changes induced in it by corticosteroid therapy: a study of 36 necropsy patients. Am. J. Med. 1975; 58: 243—264.
- Doherty N. E., Siegel R. J. Cardiovascular manifestation of systemic lupus erythematosus. Am. Heart J. 1985; 110: 1257—1265.
- Libby P., Ridker P. M., Maseri A. Inflammation and atherosclerosis. Circulation 2002; 105: 1135—1143.
- Van Doornum S., King B., Brand C. Mortality rates following a first acute cardiovascular event: a comparison between rheumatoid arthritis patients and the general population. Arthr. and Rheum. 2005; 52: 702.
- Churg C. P., Oeser A., Raggi P. Increased coronary-artery atherosclerosis in rheumatoid arthritis: relationship to disease duration and cardiovascular risk factors. Arthr. and Rheum. 2005; 52: 3045—3053.
- Solomon D. H., Karlson E. W., Rimm E. B. et al. Cardiovascular morbidity and mortality in women diagnosed with rheumatoid arthritis. Circulation 2003; 107: 1303—1307.
- Mazer S. P., Rabbani L. E. Evidence for C-reactive protein’s (CRP) role in vascular disease: atherothrombosis, immunoregulation and CRP Thromb. Thrombolys. 2004; 17: 95—105.
- Van Oostrom A. J., Van Wijk J., Cabezaz M. C. Lipaemia, inflammation and atherosclerosis: novel opportunities in the understanding and treatment of atherosclerosis. Drugs 2004; 64: 19—41.
- Everett B. M., Kurth T., Buring J. E., Ridker P. M. The relative strength of C-reactive protein and lipid levels as determinants of ischemic stroke compared with coronary heart disease in women. J. Am. Coll. Cardiol. 2006; 48 (11): 2235—2242.
- Ridker P. M., Rifai N., Pfeffer M. et al. Elevation of tumor necrosis factor-alpha and increased risk of recurrent coronary events after myocardial infarction. Circulation 2000; 101: 2149—2153.
- Biasucci L. M., Vitelli A., Liuzzo G. et al. Elevated levels of interleukin-6 in unstable angina. Circulation 1996; 94: 874—877.
- Shoenfeld Y., Gerli R., Doria A. et al. Accelerated atherosclerosis in autoimmune rheumatic diseases. Circulation 2005; 112: 3337—3347.
- Ross R. Athrosclerosis. An inflammatory disease. N. Engl. J. Med. 1999; 340: 115—126.
- Qiao J. H., Castelllani L. W., Fishbein M. C., Luis A. J. Immune complex-mediated vasculitis increases coronary artery lipid accumulation in autoimmune-prone MRL mice. Arterioscler. Thromb. 1993; 13: 932—943.
- Wick G., Romen M., Amberger A. et al. Atherosclerosis, autoimmunity, and vascular-associated lymphoid tissue. FASEB J. 1997; 11: 1199—1207.
- Shoenfeld Y., Sherer Y., Haratz D. Atherosclerosis as an infectious, inflammatory and autoimmune disease. Trends Immunol. 2001; 22: 293—295.
- van Leuven S. I., Franssen R., Kastelein J. J. et al. Systemic inflammation as a risk factor for atherothrombosis. Rheumatology 2008; 47 (1): 3—7.
- Семенкова Е. Н. Системные васкулиты. М.: Медицина; 1988.
- Семенкова Е. Н. Трудности диагностики коронарита при системных васкулитах. Тер. арх. 1994; 66 (5): 50—54.
- Schrader M., Hochman J., Bulkley B. The heart in poltarteritis nodosa: A clinicopathologic study. Am. Heart J. 1985; 109: 1353—1359.
- Wagner A. D., Feist T., Prondzinsky R. et al. Joint and muscle pain with mononeuritis multiplex, tetraparesis, and myocardial infarction in a previously healthy adult. Ann. Rheum. Dis. 2001; 60: 1003—1006.
- Kastner D., Gaffney M., Tak T. Polyarteritis nodosa and myocardial infarction. Can. J. Cardiol. 2000; 16 (4): 515—518.
- Rajani R. M., Dalvi B. V., D’Silva S. A. et al. Acute myocardial infarction with normal coronary arteries in a case of polyarteritis nodosa: possible role of coronary artery spasm. Postgrad. Med. J. 1991; 67: 78—80.
- Liozon F., Vidal E., Gaches F. et al. Death in Horton disease. Prognostic factors. Rev. Med. Interne 1992; 13 (3): 187—191.
- Freire de Carvalho J., Bonfa E., Bezerra M. C., Rodrigues Pereira R.M. High frequency of lipoprotein risk levels for cardiovascular disease in Takayasu arteritis. Clin. Rheumatol. 2009; 28 (7): 801—805.
- Seyahi E., Ugurlu S., Cumali R. et al. Atherosclerosis in Takayasu arteritis. Ann. Rheum. Dis. 2006; 65 (9): 1202—1207.
- Park K. C., Kim J. H., Yoon S. S., Heo S. H. Takayasu’s disease presenting with atherothrombotic ischaemic stroke. Neurol. Sci. 2008; 29 (5): 363—366.
- Filer A., Nicholls D., Corston R. et al. Takayasu arteritis and atherosclerosis: illustrating the consequences of endothelial damage. J. Rheumatol. 2001; 28 (12): 2752—2753.
- Faurschou M., Mellemkjaer L., Sorensen I. et al. Increased morbidity from ischemic heart disease in patients with Wegener’s granulomatosis. Arthr. and Rheum. 2009; 60 (4): 1187—1192.
- Raza K., Thambyrajah J., Townsend J. N. et al. Suppression of inflammation in primary systemic vasculitis restores vascular endothelial function: Lessons for atherosclerotic disease? Circulation 2000; 102: 1470.
- de Leeuw K., Sanders J. S., Stegeman C. et al. Accelerated atherosclerosis in patients with Wegener’s granulomatosis. Ann. Rheum. Dis. 2005; 64 (5): 753—759.
- Nienhuis H. L. A., De Leeuw K., Smit A. J. et al. Enhanced endothelium-dependent microvascular responses in patients with Wegener’s granulomatosis. J. Rheumatol. 2007; 34 (9): 1875—1881.
- Bacon P. A., Moots R. J. I. Birmingham Vasculitis Activity Score (BVAS) in systemic necrotizing vasculitis. Quart. J. Med. 1994; 87: 671—678.
- Booth A. D., Jayne D. R. W., Kharbanda R. K. et al. Infliximab improves endothelial dysfunction in systemic vasculitis. Circulation 2004; 109: 1718—1723.
- Swets B. P., Brouder A. J., Tervaert J. W. Patients with systemic vasculitis have increased levels of autoantibodies against oxidized LDL. Clin. Exp. Immunol. 2001; 124 (1): 163—167.
- Chironi G., Pagnoux C., Simon A. et al. Increased prevalence of subclinical atherosclerosis in patients with small-vessel vasculitis. Heart 2007; 93: 96—99.
- Giles J., Post W., Blumenthal R. et al. Therapy insight: managing cardiovascular risk in patients with rheumatoid arthritis. Nature Clin. Pract. Rheumatol. 2006; 2 (6): 320—329.
- Choi H. K., Hernan M. A., Seeger J. D. Methotrexate and mortality in patints with rheumatoid arthritis: a prospective study. Lancet 2002; 359: 1173—1177.
- Jacobsson L. T., Askling J., Rantapaa-Dahlvist S. Anti-TNF therapy and risk of death up to 8 years after treatment start. Results from the Swedish biologics register (ARTIS). Ann. Rheum. Dis. 2008; 67: 183.
- Gazi I. F., Boumpas D. T., Mikhalidis D. et al. Clustering of cardiovascular risk factors in rheumatoid arthritis: the rationale for using statins. Clin. Exp. Rheumatol. 2007; 25: 102—111.
- Jury E. C., Ehrenstein M. R. Statins: immunomodulators for autoimmune rheumatic disease? Lupus 2005; 14 (3): 192—196.
- Bijl M. Endothelial activation, endothelial dysfunction and premature atherosclerosis in systemic autoimmune diseases. Neth. J. Med.l 2003; 61 (9): 273—277.
- Bisoendial R., Stroes E., Kastelein J., Tak P. Tageting cardiovascular risk in rheumatoid arthritis: dual role for statins. Nature Rev. Rheumatol. 2010; 6 (3): 157—164.
- Marz W., Koenig W. HMG-CoA reductase inhibition: Anti-inflammatory effects beyond lipid lowering? J. Cardiovasc. Risk 2003; 10 (3): 169—179.